Press

PanGenomic Health Issues Letter to Shareholders

Dec 26 • 6 min read

PanGenomic Health Inc. (CSE: NARA) today issued a letter to shareholders from its executive team. Dear Shareholders, As we close out our first year as a publicly-traded company, your team at PanGenomic Health is busy laying the groundwork for success in the burgeoning health technology industry. At the core of our evidence-based health platform is…

Small Pharma Announces Completion of SPL026 Phase IIa Trial and Secures New Intellectual Property

Dec 26 • 3 min read

Small Pharma Inc. (TSXV: DMT | OTCQB: DMTTF), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that the last patient has completed its final visit in the Phase IIa clinical trial of SPL026, intravenous N,N-dimethyltryptamine (“DMT”), with supportive therapy, for the treatment of Major Depressive Disorder (“MDD”). “The last…

Beckley Psytech Launches Phase IIa Study of Lead Candidate BPL-003, a Novel Benzoate Formulation of 5-MeO-DMT, for Treatment Resistant Depression

Dec 22 • 3 min read

Beckley Psytech Ltd, a private, clinical-stage biotechnology company dedicated to addressing neuropsychiatric conditions through the novel application of psychedelic medicines, today announced that it had initiated a Phase IIa study investigating BPL-003, a proprietary intranasal formulation of synthetic 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT), for Treatment Resistant Depression (TRD). Depression affects around 280 million people around the world, but 30%…

Cybin Inc. CEO Highlights 2022 as ‘Momentous Year’

Dec 20 • 2 min read

Cybin (NYSE American: CYBN | NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today issued a year-end summary of its key milestone accomplishments in 2022. “2022 was a momentous year marked by steady progress across our pipeline of differentiated psychedelic-based therapeutics and partnerships targeting mental health. Most notable were the advancements of…

Wesana Health Announces Receipt of Short-Term Loan

Dec 20 • 2 min read

Wesana Health Holdings Inc. (CSE: WESA | OTCQB: WSNAF), a data-driven life sciences company, today announced that Wesana Health Inc., a subsidiary of the Company, has received an unsecured short-term loan in an aggregate principal amount of US$250,000 from an arm’s length lender. The Loan will bear interest at a rate of 10% per annum, which interest will…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435